ProShare Advisors LLC Has $17.58 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

ProShare Advisors LLC lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 47.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 107,879 shares of the company's stock after selling 97,697 shares during the quarter. ProShare Advisors LLC's holdings in Zoetis were worth $17,577,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Mission Wealth Management LP grew its holdings in Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after buying an additional 59 shares during the last quarter. VeraBank N.A. grew its holdings in shares of Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock worth $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC grew its holdings in shares of Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after purchasing an additional 62 shares in the last quarter. Procyon Advisors LLC grew its holdings in shares of Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company's stock worth $768,000 after purchasing an additional 63 shares in the last quarter. Finally, Coppell Advisory Solutions LLC grew its holdings in shares of Zoetis by 18.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after purchasing an additional 64 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Stifel Nicolaus decreased their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Monday, April 14th. UBS Group decreased their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis currently has an average rating of "Buy" and an average target price of $212.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. The trade was a 2.02% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Zoetis Price Performance

Zoetis stock opened at $163.03 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The company has a market capitalization of $72.58 billion, a PE ratio of 29.80, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The business has a 50 day simple moving average of $156.46 and a 200 day simple moving average of $165.43.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the previous year, the company posted $1.38 EPS. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.